Details of the poster presentation are as follows:
Title: Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR-T Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Poster Board: E1, Abstract 140
Presenter:
Time/Location:
About
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.
Investors:
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com
![](https://ml.globenewswire.com/media/ZmFjNWRiNDItYjVjYy00MzEzLWFhMzktYzVhN2JmNDhmZmZkLTEwMjgyNjg=/tiny/Bellicum-Pharmaceuticals-Inc-.png)
2023 GlobeNewswire, Inc., source